ImpriMed uses artificial intelligence and analysis of live cancer cells to predict personalized drug responses for treating canine lymphoma.

ImpriMed

ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company’s pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company’s technology has been deployed across more than 40 U.S. states, and 17,000+ canine and feline blood cancer tests have been performed as of 2024. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com.

Murex Partners

HG Initiative

Draper Associates

Draper Dragon

ES Investor

BonAngels Venture Partners

Primer Sazze Partners

Translink Investment

FuturePlay

Mayo Clinic Platform

Han River Partners

Ignite Innovation Fund

KDB Industrial Bank

Byucksan

SAMYANG CHEMICAL GROUP

SK Telecom

SBVA

Angel Investor

ImpriMed, Inc.

Thank you, TechCrunch, for highlighting our work at ImpriMed! We are on a mission to transform cancer care by empowering clinicians and aiding patients with the best predictive information for personalized treatment.

#petcare #cancercare #personalizedmedicine #precisionmedicine #biotech

🎧 New Episode Alert! 🐾
Tune into the latest episode of the Veterinary Cancer Pioneers Podcast where we're joined by Dr. Heather Wilson-Robles, Chief Medical Officer at Volition Veterinary. Dive into a captivating discussion on the transformative power of mentorship in shaping careers in veterinary oncology. Discover how Dr. Wilson-Robles's journey, from her initial inspiration in pediatric oncology to her leadership role in the industry, highlights the pivotal role of mentor-mentee relationships in professional growth.

#VeterinaryOncology #Mentorship #VeterinaryMedicine #ProfessionalGrowth #Podcast #VeterinaryCancerPioneers #Leadership

Everyone's buzzing about AI (including us)! To boost your AI knowledge, discover how AI is transforming the veterinary field in this AVMA (American Veterinary Medical Association) news article!

P.S. We're thrilled to be mentioned for our role in pioneering AI-driven personalized medicine. It's an exciting time to be part of this AI revolution! 

 #AI #VeterinaryMedicine #Innovation

Step into ImpriMed's Wall of Love! Overflowing with heartfelt support, love, and adorable photos from our amazing veterinarians and pet parents. Dive in and feel the love! 💖🐾: https://lnkd.in/giu2zN8e

#Testimonials #VetSupport #PetParentStories

"I still come across people that are like, 'Wait, dogs, they get cancer?'"
"The veterinary cancer field has done absolutely worlds of work to even get that conversation going. So I'm very proud to have come from that place."

We hear this question a lot as workers in veterinary cancer, and igniting this conversation is exactly what our podcast is all about.

Join our passionate veterinary cancer pioneers, Dr. Rachel Venable, and our new guest, Dr. Nicole Ehrhart, the Director of Colorado State University's Columbine Health Systems Center for Healthy Aging, as we dive into the vast world of veterinary cancer and its comparative aspects.

In this episode, Dr. Ehrhart shares her career journey and delves into the fascinating field of comparative cancer research. She also explores the drivers of aging, the potential of senotherapeutics, and immune regeneration in cancer treatment. Learn how she facilitates interdisciplinary research across various domains to tackle aging challenges and discover the intriguing similarities between the fundamental drivers of cancer and cellular aging.

🎧 https://lnkd.in/grvwdYVz

#veterinarycancer #pethealth #dogcancerawareness
#comparativeresearch #agingresearch #cancertreatment #podcast

Wishing you a great holiday! Celebrate with friends, family, and a good podcast. Catch our latest episode here: https://buff.ly/4cHlMC1

🎙️ The Veterinary Cancer Pioneers Podcast has a brand new episode ready for you!
Join our host, Dr. Rachel Venable, and new guest, Dr. Julius Liptak, the internationally renowned surgical oncologist.

In this episode, they dive into:
🔍 The challenges of cancer surgeries in pets
📍 The crucial role of sentinel lymph node mapping
🔄 The evolving landscape of veterinary oncology
📊 The need for robust data to guide treatments

🔗:https://lnkd.in/gzBPvZmq

#VeterinaryOncology #PetHealth #CancerSurgery

Team ImpriMed—Mitch Buntemeyer, Collin H. Cavanaugh, and Melody Jung—had an amazing experience at the #2024ACVIMForum in Minneapolis, Minnesota! It was wonderful meeting attendees from around the globe and exploring the vibrant city of Minneapolis. We made valuable connections and are already looking forward to seeing everyone in Louisville, KY, for the 2025 Forum! 🌍

#VeterinaryMedicine #TeamImpriMed #Minneapolis #ACVIM #Louisville2025

💖🐾 Featuring the Adorable Kyle Today! 🐾

We received this heartwarming photo from Dr. Sarah Furtney, a Relief Veterinarian at Animology.

“I just wanted to express my gratitude for ImpriMed's help. The work you do is profound, not only does it prolong life for pets, but their humans as well. I'm not sure if you ever get pictures of the pets you are helping, but I'm hoping that Kyle's picture expresses the magnitude of your work.”

Thank you, Dr. Sarah Furtney! We are truly honored. 

#thankyouvets #caninelymphoma #australianshepherd

🧬🐶Our furry friends are crucial allies in the fight against cancer!

Join Dr. Rachel Venable as she dives into conversation with Dr. Amy LeBlanc, a Senior Scientist and Director at the The National Institutes of Health
’s CCR Comparative Oncology Program.

Explore the compelling integration of canine models into cancer research and the translational benefits that dogs offer in understanding and treating human cancers. Dr. LeBlanc also discusses her team’s work with naturally occurring cancers in pets, offering new hope to both humans and animals. 

📹 Tune in for this revolutionary discussion: https://lnkd.in/gu4ZVnZS

#CancerResearch #VeterinaryOncology #PodcastPreview #InnovativeTherapies

Metric
Company Name	ImpriMed
Symbol
MSH ID	COM:IMPRIMEDICINE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Veterinary Oncology
Country	US
Stage
Employee Count
Website	imprimedicine.com
LinkedIn	imprimed-inc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IMPR

COM:IMPRIMEDICINE

ImpriMed

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue